WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2002031136) ANTISENSE MODULATION OF BCAS1 EXPRESSION
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2002/031136    International Application No.:    PCT/US2001/031484
Publication Date: 18.04.2002 International Filing Date: 09.10.2001
Chapter 2 Demand Filed:    07.05.2002    
IPC:
A61K 48/00 (2006.01), C07K 14/47 (2006.01)
Applicants: ISIS PHARMACEUTICALS, INC. [US/US]; 2292 Faraday Avenue, Carlsbad, CA 92008 (US) (For All Designated States Except US).
COWSERT, Lex, M. [US/US]; (US) (For US Only).
FREIER, Susan, M. [US/US]; (US) (For US Only)
Inventors: COWSERT, Lex, M.; (US).
FREIER, Susan, M.; (US)
Agent: LICATA, Jane, Massey; Licata & Tyrrell P.C., 66 E. Main Street, Marlton, NJ 08053 (US)
Priority Data:
09/689,255 11.10.2000 US
Title (EN) ANTISENSE MODULATION OF BCAS1 EXPRESSION
(FR) MODULATION ANTISENS DE L'EXPRESSION DE LA SEQUENCE BCAS1
Abstract: front page image
(EN)Antisense compounds, compositions and methods are provided for modulating the expression of BCAS1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding BCAS1. Methods of using these compounds for modulation of BCAS1 expression and for treatment of diseases associated with expression of BCAS1 are provided.
(FR)L'invention concerne des composés antisens, des compositions et des méthodes, permettant de moduler l'expression de la séquence BCAS1. Ces compositions renferment des composés antisens, en particulier des oligonucléotides antisens, ciblés sur les acides nucléiques codant pour la séquence BCAS1. L'invention concerne également des méthodes d'utilisation de ces composés destinées à la modulation de l'expression de la séquence BCAS1 et des méthodes destinées au traitement de pathologies associées à l'expression de la séquence BCAS1.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)